HCW Biologics Inc
Company Profile
Business description
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
Contact
2929 N Commerce Parkway
MiramarFL33025
USAT: +1 954 842-2024
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
36
Stocks News & Analysis
stocks
2 companies poised to capitalize on the rise of GLP-1 drugs
stocks
Does this bank have what it takes to compete with the big 4?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,875.80 | 20.30 | -0.23% |
| CAC 40 | 8,052.51 | 55.92 | -0.69% |
| DAX 40 | 24,172.29 | 126.28 | 0.53% |
| Dow JONES (US) | 47,885.68 | 146.36 | 0.31% |
| FTSE 100 | 9,642.01 | 3.08 | -0.03% |
| HKSE | 25,434.23 | 331.13 | -1.29% |
| NASDAQ | 23,590.80 | 44.90 | 0.19% |
| Nikkei 225 | 50,655.10 | 73.16 | 0.14% |
| NZX 50 Index | 13,454.78 | 31.54 | -0.23% |
| S&P 500 | 6,863.81 | 17.30 | 0.25% |
| S&P/ASX 200 | 8,585.90 | 20.50 | -0.24% |
| SSE Composite Index | 3,909.52 | 14.56 | -0.37% |